Neil Moat, one of the busiest British surgeons involved directly and consistently in TAVR, discusses PARTNER 2 and SURTAVI, paying particular attention to the health economics of low-risk TAVR and the implication of reduced profile devices.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
March 20, 2016
This instructive paper includes three separate meta-analyses focusing on patient-prosthesis mismatch (PPM) after TAVR. These meta-analyses revealed the following:
September 23, 2015
The authors conducted a propensity-matched analysis of outcomes and costs associated with TAVR vs. SAVR procedures in patients considered either intermediate risk (STS PROM 4-8%) or high risk (STS PROM >8%) within the Commonwealth of Virginia.
August 3, 2015
In this manuscript the authors describe their findings in a retrospective review of prospectively obtained 5-year follow up data on 353 patients undergoing transcatheter aortic valve implantation (TAVI) with the CoreValve prosthesis in 8 Italian centres.Transfemoral access was used in 317 patients (89.8%); in the rest of the patients in whom the tran
June 19, 2015
The FDA approved Edwards' Sapien third generation transcatheter aortic valve, designed to limit paravalvular leakage by incorporating a skirt at the base of the valve. The approval was based on results of the PARTNER II S3 study, which demonstrated improved rates of paravalvular leakage at 30 days (<4%) compared to 10% to 20% rates for other valv
2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement
June 17, 2015
In this paper the authors report on the 2-year results of the randomized US pivotal trial for surgical and self-expanding percutaneous aortic prosthetic valves. The survival benefit observed at 1 year in the transcatheter group were sustained at two years.
Perioperative Results and Complications in 15,964 Transcatheter Aortic Valve Replacements: Prospective Data From the GARY Registry.
June 14, 2015
In this manuscript the authors report on data from the German Aortic Valve Registry (GARY) comprising 15964 transcatheter aortic valve replacement (TAVR) procedures performed from 2011 to 2013 evaluating severe vital complications (SVCs), technical complications of the procedures (TCOs), other complications, conversion to sternotomy and in-hospital d
June 13, 2015
In this open-access article, the authors describe their findings in a systematic review of transcatheter heart valve (THV) failures, comprising 70 articles and 87 individual cases. Unusual complications such as late embolization (mostly into the left ventricle) and prosthetic compression (exclusively in balloon expandable THVs) are described.
April 24, 2015
In this manuscript the authors describe a systematic review of 71 cases of transcatheter heart valve embolization. In 72% of the patients, the prosthesis used was a balloon expandable one. In most cases valve embolization occurred soon after implantation and it happened in the aortic direction.
Aortic valve calcium score is a significant predictor for the occurrence of post-interventional paravalvular leakage after transcatheter aortic valve implantation — Results from a single center analysis of 260 consecutive patients
December 30, 2014
This is a retrospective review of 260 patients undergoing TAVI, looking at the relationship between aortic valve calcium score and post procedural paravalvular leakage. The results suggest that the amount of calcification significantly impacts the occurrence, the degree and localization of paravalvular leakage after TAVI.